Article
Oncology
Myeong-Seon Kim, Seung Hun Baek, Joseph J. Noh, Jung In Shim, Jun Hyeok Kang, Soo Young Jeong, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Yoo-Young Lee
Summary: This study investigated the incidence of reactive thrombocytosis and its impact on survival in patients with advanced epithelial ovarian cancer (EOC) after maximal cytoreductive surgery. The results showed that thrombocytosis was observed in 34.8% of patients one week after surgery, and it had the most significant effects on overall survival when observed during adjuvant chemotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
David Pierce Mysona, Sharad Ghamande, Jin-Xiong She, Lynn Tran, Paul Tran, Bunja J. Rungruang, John K. Chan, Victoria Bae-Jump, Paola A. Gehrig
Summary: This study found that IDS was associated with lower overall survival, and a CGR at PDS had prolonged median OS compared to a CGR at IDS. Continued efforts should be made to improve cytoreductive outcomes in women with advanced ovarian and peritoneal malignancies.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Antoni Llueca, Maria Teresa Climent, Javier Escrig, Paula Carrasco, Anna Serra, L. Gomez-Quiles, R. Jativa, G. Cebrian, V Bosso, A. Villarin, K. Maiocchi, K. Delgado-Barriga, M. Rodrigo-Aliaga, N. Ruiz, C. Herrero, A. Frances, I Beato, C. Ferrer, J. P. Aracil, E. Boldo, A. Boldo, R. Adell
Summary: This study validated the predictive value of three models for predicting suboptimal cytoreductive surgery in advanced ovarian cancer, showing better reliability in predicting complete cytoreductive surgery.
SCIENTIFIC REPORTS
(2021)
Correction
Medicine, General & Internal
Philipp Harter, Jalid Sehouli, Ignace Vergote, Gwenael Ferron, Alexander Reuss, Werner Meier, Stefano Greggi, Berit J. Mosgard, Frederic Selle, Frederic Guyon, Christophe Pomel, Fabrice Lecuru, Rongyu Zang, Elisabeth Avall-Lundqvist, Jae-Weon Kim, Jordi Ponce, Francesco Raspagliesi, Gunnar Kristensen, Jean-Marc Classe, Peter Hillemanns, Pernille Jensen, Annette Hasenburg, Sadaf Ghaem-Maghami, Mansoor R. Mirza, Bente Lund, Alexander Reinthaller, Ana Santaballa, Adeola Olaitan, Felix Hilpert, Andreas du Bois
Summary: In patients with recurrent ovarian cancer, cytoreductive surgery followed by chemotherapy resulted in longer overall survival than chemotherapy alone. Patients with a complete resection had the most favorable outcome.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
N. M. S. Baldewpersad Tewarie, W. J. van Driel, M. van Ham, M. W. Wouters, R. Kruitwagen
Summary: The study found that patients undergoing primary debulking surgery had a higher rate of complete cytoreduction but also a higher rate of complications requiring re-intervention, resulting in a longer time to start adjuvant chemotherapy. It is important to balance the aggressiveness of surgery with the outcomes of severe complications to improve the quality of surgical outcomes.
GYNECOLOGIC ONCOLOGY
(2021)
Review
Medicine, General & Internal
Shaun Hiu, Andrew Bryant, Ketankumar Gajjar, Patience T. Kunonga, Raj Naik
Summary: This retrospective study evaluated the effectiveness and morbidity associated with ultra-radical/extensive surgery in the treatment of advanced-stage epithelial ovarian cancer. The results suggest that ultra-radical surgery may reduce the risk of mortality, but the evidence is very uncertain. The study also found that ultra-radical surgery may increase the risk of disease progression or death. Due to the risk of bias in these studies, quality of life and morbidity outcomes were not adequately reported.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Review
Oncology
Alexander Melamed, Eric L. Eisenhauer
Summary: With the increasing use of neoadjuvant chemotherapy, it is apparent that some patients may benefit from less extensive interval cytoreductive surgery performed using minimally invasive techniques. Surgeons in various countries, including the United States, have started adopting these techniques based on their expertise in minimally invasive surgery for other indications in gynecologic oncology. Further research will determine the most suitable patients for this approach.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Gatske M. M. Nieuwenhuyzen-de Boer, Hanane Aamran, Caroline B. B. van den Berg, Sten Willemsen, Jurgen M. J. Piek, Nathalie Reesink-Peters, Marianne Maliepaard, Helena C. van Doorn, Suzanne Polinder, Heleen J. van Beekhuizen
Summary: This study aimed to determine whether the use of the PlasmaJet Surgical device during surgery has an effect on the quality-of-life of patients with advanced ovarian cancer. The results showed that using the PlasmaJet device during surgery leads to a higher quality-of-life compared to surgery with electrocoagulation alone. The differences in quality-of-life mainly relate to physical and role functioning, fatigue, and pain.
Review
Obstetrics & Gynecology
Benjamin B. Albright, Karen A. Monuszko, Samantha J. Kaplan, Brittany A. Davidson, Haley A. Moss, Allan B. Huang, Alexander Melamed, Jason D. Wright, Laura J. Havrilesky, Rebecca A. Previs
Summary: This study summarized evidence on primary cytoreductive surgery in the treatment of advanced stage endometrial cancer. The meta-analysis showed that a significant proportion of patients with advanced stage endometrial cancer undergoing primary cytoreductive surgery still had residual disease, which was associated with worse survival outcomes. Further investigation in prospective trials is needed to explore the roles of neoadjuvant chemotherapy and primary cytoreductive surgery in this population.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Article
Medicine, General & Internal
Henri Azais, Anne-Sophie Vignion-Dewalle, Marine Carrier, Jeremy Augustin, Elisabeth Da Maia, Alix Penel, Jeremie Belghiti, Marianne Nikpayam, Clementine Gonthier, Laurine Ziane, Serge Mordon, Pierre Collinet, Geoffroy Canlorbe, Catherine Uzan
Summary: The study found that there is a 98.14% probability of residual microscopic peritoneal metastases (mPM) after complete macroscopic cytoreductive surgery (CRS) for EOC patients. Microscopic PM could be a relevant therapeutic target in the treatment of EOC.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Sabrina Piedimonte, Lauren Erdman, Delvin So, Marcus Q. Bernardini, Sarah E. Ferguson, Stephane Laframboise, Genevieve Bouchard Fortier, Paulina Cybulska, Taymaa May, Liat Hogen
Summary: This study developed a machine learning algorithm to predict the outcome of primary cytoreductive surgery in patients with advanced ovarian cancer. The algorithm demonstrated high accuracy in predicting optimal cytoreduction and may assist in decision-making.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Caixia Jiang, Yingwei Liu, Junying Tang, Zhengyu Li, Wenjiao Min
Summary: Two nomograms were established to predict the risk of postoperative complications in AEOC patients following cytoreductive surgery. Factors such as modified frailty index, FIGO stage, and Surgical Complexity Score were found to be significantly associated with overall and severe complications. The nomograms showed good discrimination and calibration, indicating their potential utility in guiding clinical decision-making for AEOC patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
P. Harter, J. Sehouli, I Vergote, G. Ferron, A. Reuss, W. Meier, S. Greggi, B. J. Mosgard, F. Selle, F. Guyon, C. Pomel, F. Lecuru, R. Zang, E. Avail-Lundqvist, J-W Kim, J. Ponce, F. Raspagliesi, G. Kristensen, J-M Classe, P. Hillemanns, P. Jensen, A. Hasenburg, S. Ghaem-Maghami, M. R. Mirza, B. Lund, A. Reinthaller, A. Santaballa, A. Olaitan, F. Hilpert, A. du Bois
Summary: The study demonstrates that in patients with recurrent ovarian cancer, secondary cytoreductive surgery followed by chemotherapy results in longer overall survival compared to chemotherapy alone. Quality of life measures did not differ significantly between the two treatment groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Berta Diaz-Feijoo, Nuria Agusti-Garcia, Raquel Sebio, Antonio Lopez-Hernandez, Marina Siso, Ariel Glickman, Nuria Carreras-Dieguez, Pere Fuste, Tiermes Marina, Judit Martinez-Egea, Laura Aguilera, Juan Perdomo, Amaia Pelaez, Manuel Lopez-Baamonde, Ricard Navarro-Ripoll, Elena Gimeno, Betina Campero, Aureli Torne, Graciela Martinez-Palli, Maria J. Arguis
Summary: Multimodal prehabilitation programmes before surgery are feasible and safe in patients with advanced ovarian cancer, and result in shorter hospital stays and time to starting chemotherapy.
Review
Oncology
M. P. Engbersen, M. J. Lahaye, C. A. R. Lok, S. N. Koole, G. S. Sonke, R. G. H. Beets-Tan, W. J. Van Driel
Summary: Objective scoring systems can assist in determining the feasibility of complete or optimal cytoreductive surgery, however with current data, no scoring system has been identified as superior. Due to variations in cutoff points, sensitivities and specificities greatly differ.
